Maze Therapeutics (NASDAQ:MAZE) CMO Sells $441,900.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 15,000 shares of the stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $29.46, for a total value of $441,900.00. Following the completion of the transaction, the chief marketing officer owned 15,000 shares in the company, valued at $441,900. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harold Bernstein also recently made the following trade(s):

• On Friday, March 20th, Harold Bernstein sold 15,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $49.10, for a total value of $736,500.00.
• On Tuesday, March 10th, Harold Bernstein sold 30,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $50.45, for a total value of $1,513,500.00.
• On Monday, February 2nd, Harold Bernstein sold 15,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $46.02, for a total value of $690,300.00.
• On Wednesday, January 7th, Harold Bernstein sold 25,156 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.20, for a total value of $1,011,271.20.
• On Monday, January 5th, Harold Bernstein sold 412 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.00, for a total value of $16,480.00.
• On Friday, January 2nd, Harold Bernstein sold 4,432 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.43, for a total value of $179,185.76.

Maze Therapeutics Stock Performance

Maze Therapeutics stock opened at $28.71 on Friday. The company has a market cap of $1.43 billion, a PE ratio of -8.89 and a beta of 5.16. Maze Therapeutics, Inc. has a 1 year low of $6.71 and a 1 year high of $53.65. The company’s 50-day moving average is $44.13 and its two-hundred day moving average is $38.01.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings results on Wednesday, March 25th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.08.

Institutional Investors Weigh In On Maze Therapeutics

Hedge funds have recently bought and sold shares of the company. Frazier Life Sciences Management L.P. grew its holdings in shares of Maze Therapeutics by 10.6% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock valued at $56,040,000 after buying an additional 438,274 shares during the period. Janus Henderson Group PLC raised its stake in Maze Therapeutics by 318.0% during the 4th quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after buying an additional 2,390,713 shares during the period. Vanguard Group Inc. lifted its holdings in Maze Therapeutics by 27.1% during the fourth quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company’s stock worth $70,307,000 after acquiring an additional 362,060 shares in the last quarter. Woodline Partners LP lifted its holdings in Maze Therapeutics by 10.0% during the third quarter. Woodline Partners LP now owns 1,035,229 shares of the company’s stock worth $26,843,000 after acquiring an additional 94,529 shares in the last quarter. Finally, Marshall Wace LLP grew its stake in Maze Therapeutics by 9.0% in the fourth quarter. Marshall Wace LLP now owns 847,472 shares of the company’s stock valued at $35,111,000 after acquiring an additional 69,771 shares during the period.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Guggenheim upped their target price on shares of Maze Therapeutics from $46.00 to $58.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Lifesci Capital upgraded Maze Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. BTIG Research reaffirmed a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a research note on Wednesday, March 25th. Weiss Ratings reiterated a “sell (d)” rating on shares of Maze Therapeutics in a report on Thursday, January 22nd. Finally, Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $66.44.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.